Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis - PubMed (original) (raw)

Review

. 2012 Nov 10;380(9854):1662-73.

doi: 10.1016/S0140-6736(12)61350-6. Epub 2012 Sep 24.

Kunihiro Matsushita, Mark Woodward, Henk J G Bilo, John Chalmers, Hiddo J Lambers Heerspink, Brian J Lee, Robert M Perkins, Peter Rossing, Toshimi Sairenchi, Marcello Tonelli, Joseph A Vassalotti, Kazumasa Yamagishi, Josef Coresh, Paul E de Jong, Chi-Pang Wen, Robert G Nelson; Chronic Kidney Disease Prognosis Consortium

Collaborators, Affiliations

Review

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis

Caroline S Fox et al. Lancet. 2012.

Erratum in

Abstract

Background: Chronic kidney disease is characterised by low estimated glomerular filtration rate (eGFR) and high albuminuria, and is associated with adverse outcomes. Whether these risks are modified by diabetes is unknown.

Methods: We did a meta-analysis of studies selected according to Chronic Kidney Disease Prognosis Consortium criteria. Data transfer and analyses were done between March, 2011, and June, 2012. We used Cox proportional hazards models to estimate the hazard ratios (HR) of mortality and end-stage renal disease (ESRD) associated with eGFR and albuminuria in individuals with and without diabetes.

Findings: We analysed data for 1,024,977 participants (128,505 with diabetes) from 30 general population and high-risk cardiovascular cohorts and 13 chronic kidney disease cohorts. In the combined general population and high-risk cohorts with data for all-cause mortality, 75,306 deaths occurred during a mean follow-up of 8·5 years (SD 5·0). In the 23 studies with data for cardiovascular mortality, 21,237 deaths occurred from cardiovascular disease during a mean follow-up of 9·2 years (SD 4·9). In the general and high-risk cohorts, mortality risks were 1·2-1·9 times higher for participants with diabetes than for those without diabetes across the ranges of eGFR and albumin-to-creatinine ratio (ACR). With fixed eGFR and ACR reference points in the diabetes and no diabetes groups, HR of mortality outcomes according to lower eGFR and higher ACR were much the same in participants with and without diabetes (eg, for all-cause mortality at eGFR 45 mL/min per 1·73 m(2) [vs 95 mL/min per 1·73 m(2)], HR 1·35; 95% CI 1·18-1·55; vs 1·33; 1·19-1·48 and at ACR 30 mg/g [vs 5 mg/g], 1·50; 1·35-1·65 vs 1·52; 1·38-1·67). The overall interactions were not significant. We identified much the same findings for ESRD in the chronic kidney disease cohorts.

Interpretation: Despite higher risks for mortality and ESRD in diabetes, the relative risks of these outcomes by eGFR and ACR are much the same irrespective of the presence or absence of diabetes, emphasising the importance of kidney disease as a predictor of clinical outcomes.

Funding: US National Kidney Foundation.

Copyright © 2012 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

KM’s institution has received grants from the US National Kidney Foundation, Amgen, and US National Institutes of Health. MW’s institution has received a grant from Servier; he has received consultancy fees from Roche and speaker’s fees from Sanofi and Servier. JCh’s institution has received grants from Servier; and he has received speaker’s fees from them. HJLH has served as a consultant for Abbott, Reata, Johnson & Johnson, and Vitae; and he has received speaker’s fees from Abbott. BJL has received travel expenses from Kidney Disease: Improving Global Outcomes. RMP has received grants from the US National Kidney Foundation. PR’s institution has received consultancy fees from Abbott, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Lilly, and Novo Nordisk, and has received grants from Abbott, Novartis, Pfizer, and speaker’s fees from Abbott, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Lilly, and Novo Nordisk; he holds stock in Novo Nordisk. JAV has received consultancy fees from CTI Clinical Trial Services and Litholink Chronic Kidney Disease Advisory Board; his institution has received grants from the US National Institutes of Health; and he has received speaker’s fees from Gore Creative Technologies and Elsevier. JCo’s institution has received grants from the US National Kidney Foundation, US National Institutes of Health, and Amgen, and has received consultancy fees from Amgen and Merck. PEdJ’s institution has received a grant from the Dutch Kidney Foundation. CSF, HJGB, TS, MT, KY, C-PW and RGN declare that they have no conflicts of interest.

Figures

Figure 1

Figure 1. Hazard ratios for all-cause and cardiovascular mortality in the combined general and high-risk populations according to eGFR in individuals with and without diabetes

(A, B) All-cause mortality. (C, D) Cardiovascular mortality. Panels A and C use one reference point (diamond, eGFR of 95 mL/min per 1·73 m2 in the no diabetes group) for both individuals with and without diabetes to show the main effect of diabetes on risk. Panels B and D use separate references (diamonds) in the diabetes and no diabetes groups to assess interaction with diabetes specifically. Hazard ratios were adjusted for age, sex, race, smoking, history of cardiovascular disease, serum total cholesterol concentration, body-mass index, and albuminuria (log albumin-to-creatinine ratio, log protein-to-creatinine, or categorical dipstick proteinuria [negative, trace, 1+, ≥2+]). Blue and red circles denote p<0·05 as compared with the reference (diamond). Significant interaction between diabetes and eGFR is shown by x signs. eGFR=estimated glomerular filtration rate.

Figure 2

Figure 2. Hazard ratios for all-cause and cardiovascular mortality in the combined general and high-risk populations according to ACR in participants with and without diabetes

(A, B) All-cause mortality. (C, D) Cardiovascular mortality. Panels A and C use one reference point (diamond, ACR of 5 mg/g in the no diabetes group), for both individuals with and without hypertension to show the main effect of diabetes on risk. Panels B and D use separate references (diamonds) in the diabetes and no diabetes groups to assess interaction with diabetes specifically. Hazard ratios were adjusted for age, sex, race, smoking, history of cardiovascular disease, serum total cholesterol concentration, body-mass index, and estimated glomerular filtration rate. Blue and red circles denote p<0·05 as compared with the reference (diamond). Significant interaction between diabetes and ACR is shown by x signs. ACR=albumin-to-creatinine ratio.

Figure 3

Figure 3. Hazard ratios for end-stage renal disease in the chronic kidney disease populations according to eGFR and ACR in participants with and without diabetes

(A, B) eGFR. (C, D) ACR. Panels A and C use eGFR of 50 mL/min per 1·73 m2 (A) and ACR of 20 mg/g (C) in individuals without diabetes as the reference point (diamond) for both individuals with and without diabetes. Panels B and D use eGFR of 50 mL/min per 1·73 m2 (B) and ACR of 20 mg/g (D) as the reference points (diamond) in diabetic and non-diabetic groups. Blue and red circles denote p<0·05 as compared with the reference (diamond). Hazard ratios were adjusted for age, sex, race, smoking, history of cardiovascular disease, serum total cholesterol concentration, body-mass index, and albuminuria (log albumin-to-creatinine ratio, log protein-to-creatinine, or categorical dipstick proteinuria [negative/ trace, 1+, 2+, ≥3+]) or eGFR. eGFR=estimated glomerular filtration rate. ACR=albumin-to-creatinine ratio.

Figure 4

Figure 4. Hazard ratios for all-cause mortality according to eGFR in participants with and without diabetes in individuals with and without hypertension from the general population and high-risk cohorts

(A, B) Individuals with hypertension. (C, D) Individuals without hypertension. Blue and red circles denote p<0·05 as compared with the reference (diamond). Significant interaction between diabetes and eGFR is shown by x signs. Hazard ratios were adjusted for age, sex, race, smoking, history of cardiovascular disease, serum total cholesterol concentration, body-mass index, and albuminuria (log albumin-to-creatinine ratio, log protein-to-creatinine, or categorical dipstick proteinuria [negative, trace, 1+, ≥2+])

Comment in

Similar articles

Cited by

References

    1. Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med. 2006;354:997–99. - PubMed
    1. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005;365:331–40. - PubMed
    1. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28. - PubMed
    1. Hallan SI, Coresh J, Astor BC, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17:2275–84. - PubMed
    1. Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol. 2003;14(suppl 2):S131–38. - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources